Auron seals series A for cancer therapy

The Newton, Massachusetts–based company Auron Therapeutics has received $48 million in series A financing from investors including DCVC Bio and Eli Lilly and Company . Auron will expand its machine learning platform to identify novel drug targets for reining in cancer. The goal is for these drugs to stop tumor cells from proliferating haphazardly, forcing them instead to differentiate into more mature cells or self-destruct.